Nxstage Medical (NXTM) Reports In-Line Q4 EPS; Issues Light FY16 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
February 11, 2016 9:23 AM ESTPiper Jaffray maintained an Overweight rating on NxStage Medical (NASDAQ: NXTM), and cut the price target to $23.00 (from $24.00), following the company's 4Q earnings report. Revenue exceeded expectations, while net loss was in-line with Street estimates. 2016 revenue guidance was lower than Street estimates due to a $20M... More
